We are very pleased to announce that Mr Andrew Powell has joined the Board of NeuDrive Limited as a non-executive Director.
In over 20 years as an executive leader in the life sciences industry, Andrew Powell has participated in generating more than $20B in shareholder value through a series of successful transactions. He has worked with fast growing companies through transformative stages in their development, ultimately helping to create, and then execute, three of the largest biotech deals of the decade: the sale of Medivation to Pfizer; the sale of InterMune to Roche; and the sale of ImClone Systems to Lilly.
Trained as a lawyer, he has been able to organise and motivate diverse teams to see the strategic intersection between risk management (dull) and value creation (exciting). He played a key role developing ImClone, InterMune and Medivation into rigorous commercial organisations that were both compliant and equipped for growth in the U.S. and beyond. Similarly, at CollaGenex Pharmaceuticals and Cornerstone Therapeutics, he helped dynamic leadership navigate change and reinvent IP and regulatory strategies to multiply shareholder value.
At the start of his career Mr. Powell spent several years with Baxter International, working on the ground to expand their business in multiple countries, and negotiating (and ultimately managing) more than a dozen ex-U.S. joint ventures in China and developing countries in Asia and Latin America. His interest in promoting economic development remains strong, and he currently serves as an advisor to the WIN and Red Segura non-profit healthcare initiatives, focused on improving delivery of healthcare to underserved populations in Senegal and Honduras respectively.
He serves on the boards of Aclaris, Inc., a NASDAQ listed biotech company, Cure Network Ventures, an enterprise of the Gladstone Institutes at the University of California, focused on facilitating the development and commercialization of breakthrough research in cardiology and neurology, and Sciaderm, Inc. a start-up specialty pharma company. He has also served as a director of BioLeap, Inc. a start-up computational chemistry company. As a Member of the Band of Angels, he also plays a number of advisory roles supporting angel investors and angel funded technology companies in the San Francisco Bay Area.
Mr. Powell attended Winchester College in England, graduated as a Morehead Scholar from the University of North Carolina at Chapel Hill, and earned a Juris Doctor degree at Stanford.